Variation of COMT Val158Met Polymorphism Between COM-ON Patients and METHADOSE Patients

Assistance Publique - Hôpitaux de Paris

Status: Completed

Conditions: Opiate Dependence; Opiate Addiction; Opiate Abuse; Opioid-related Disorders

Treatments: Genetic: COMT polymorphism

Study type: Observational

Funder types: Other

Identifiers

NCT01570699

CRC10 073

2011-A00623-38 (Other Identifier)

Details and patient eligibility

About

The main objective is to compare the genotypes of the COMT Val158Met polymorphism between opiate-users and opiate-dependent subjects. The secondary objective is to constitute a sample of opiate-users without any lifetime opiate dependence.

Full description

The COMT enzyme enables the degradation of brain monoamines such as Dopamine and is encoded by a single gene for which several polymorphisms are known, including the Val158Met polymorphism which has been widely studied in various psychiatric disorders, including addictions, as well as in impulsivity. In most studies it is the Val allele which is found to be associated with addictive behaviors. The study METHADOSE, which began in 2009, includes opiate-dependent patients substituted by methadone. The preliminary analysis of this study shows a genotype distribution different from that of general population samples, with a greater prevalence of Val / Val and Val / Met genotypes. Will be included in the COM ON study subjects who have consumed illicit opiates (heroin, methadone, buprenorphine or morphine) more than 10 times in their life, without ever having the DSM-IV criteria for opiate dependence or abuse. The study will compare, by means of saliva samples, Val / Val and Val / Met genotypes between the subjects recruited in COM ON and those recruited in METHADOSE. Will also be included auto-questionnaires to identify psychological factors that may constitute risk or protective factors vis-à-vis the development of dependence.

Enrollment: 87 patients

Sex: All

Ages: 35+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patient over 18 years old
• Caucasian patients
• Clinical diagnosis of lifetime opiate-using disorder (consumption over 10 times of illicit opiates (heroin, buprenorphine, methadone or morphine))
• Not lifetime history of opioid dependence (DSMIV)
• Patients with health insurance coverage
• Patient was treated with opioids analgesics to alleviate 2 or 3 in their lives

Exclusion criteria

• Non-Caucasian patients
• Patients who cannot give their consent and/or who refuse the collection of genetic data
• Patients with no health insurance coverage

Trial design

87 participants in 2 patient groups

2: patients included in METHADOSE study

Description:

includes opiate-dependent patients substituted by methadone

Treatment:

Genetic: COMT polymorphism

1: opiate-non dependent patients

Description:

Will be included in the COM ON study subjects who have consumed illicit opiates (heroin, methadone, buprenorphine or morphine) more than 10 times in their life, without ever having the DSM-IV criteria for opiate dependence or abuse

Treatment:

Genetic: COMT polymorphism